217 results on '"Wiertlewski S"'
Search Results
2. Developing tools to evaluate quality of care management for patients living with multiple sclerosis: An original French initiative
- Author
-
Veillard, D., Deburghgraeve, V., Le Page, E., Debouverie, M., Wiertlewski, S., Gallien, P., and Edan, G.
- Published
- 2022
- Full Text
- View/download PDF
3. Evaluation of the quality of the care pathway for patients with multiple sclerosis in France: Results of an original study of a cohort of 700 patients
- Author
-
Veillard, D., Le Page, E., Epstein, J., Wiertlewski, S., Gallien, P., Hamonic, S., Debouverie, M., and Edan, G.
- Published
- 2022
- Full Text
- View/download PDF
4. Cost-utility of oral methylprednisolone in the treatment of multiple sclerosis relapses: Results from the COPOUSEP trial
- Author
-
Lallement, F., Cohen, M., Blanchard, C., Sartori, E., Demarco, O., Rouhart, F., Papeix, C., Taurin, G., Anani, T., Kassiotis, P., Hamon, C., Lester, M.A., Merienne, M., Michel, M., Le Page, E., Laplaud, D.A., Wardi, R., Lebrun, C., Zagnoli, F., Wiertlewski, S., Coustans, M., Edan, G., Chevreul, K., and Veillard, D.
- Published
- 2022
- Full Text
- View/download PDF
5. Infections and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society
- Author
-
Papeix, C., Donzé, C., Lebrun-Frénay, C., Laplaud, D., Thouvenot, E., Ayrignac, X., Pourcher-Martinez, V., Zéphir, H., de Seze, J., Michel, L., Bensa, C., Cara-Dalliere, C., Guen-noc, A.M., Casez, O., Maarouf, A., Bourre, B., Kwiatkowski, A., Cohen, M., Maillart, E., Collongues, N., Louapre, C., Androdias, G., Guegen, A., Audoin, B., Mattey, G., Bernady, P., Faucheux, J.M., Labauge, P., Meckies, C., Stankoff, B., Tourniaire, P., Dinh, A., Guennoc, A.M., Durnad-Dubief, F., Wiertlewski, S., Derache, N., Le page, E., Pittion, S., Vukusic, S., Clavelou, P., Heinzlef, O., Colamarino, R., Planque, E., Rico, A., Sheiber nogueira, C., de Seze, M., Ciron, J., Alchaar, H., Bensmail, D., Biotti, D., Branger, P., Brochet, B., Castan, B., Creange, A., Creisson, E., DeBroucker, T., Depaz, R., Douay, X., Dulau, C., Faucher, M., Fournier, M., Fromont, A., Gallien, P., Gout, O., Grimaud, J., Hervé, Y., Kerbrat, A., Kremer, L., Lanotte, L., Magy, L., Mania, A., Maurousset, A., Moisset, X., Montcuquet, A., Moreau, T., Morel, N., Patry, I., Peaureaux, D., Pouget, M.C., Ruet, A., Saint-Val, C., Stahl, J.P., Taithe, F., Tattevin, P., Vaillant, M., Vuoto, F., and Donze, C.
- Published
- 2021
- Full Text
- View/download PDF
6. SMILE: a predictive model for Scoring the severity of relapses in MultIple scLErosis
- Author
-
Lejeune, F., Chatton, A., Laplaud, D.-A., Le Page, E., Wiertlewski, S., Edan, G., Kerbrat, A., Veillard, D., Hamonic, S., Jousset, N., Le Frère, F., Ouallet, J.-C., Brochet, B., Ruet, A., Foucher, Y., and Michel, Laure
- Published
- 2021
- Full Text
- View/download PDF
7. Immunization and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society
- Author
-
Abadie, V., Achour, C., Ader, F., Alchaar, H., Alkhedr, A., Andreux, F., Androdias, G., Arjmand, R., Audoin, B., Audry, D., Aufauvre, D., Autreaux, C., Ayrignac, X., Bailbe, M., Benazet, M., Bensa, C., Bensmail, D., Berger, E., Bernady, P., Bertagna, Y., Biotti, D., Blanchard-Dauphin, A., Bonenfant, J., Bonnan, M., Bonnemain, B., Borgel, F., Botelho-Nevers, E., Boucly, S., Bourre, B., Boutière, C., Branger, P., Brassat, D., Bresch, S., Breuil, V., Brochet, B., Brugeilles, H., Bugnon, P., Cabre, P., Camdessanché, J.-P., Carra-Dalière, C., Casez, O., Chamouard, J.-M., Chassande, B., Chataignier, P., Chbicheb, M., Chenet, A., Ciron, J., Clavelou, P., Cohen, M., Colamarino, R., Collongues, N., Coman, I., Corail, P.-R., Courtois, S., Coustans, M., Creange, A., Creisson, E., Daluzeau, N., Davenas, C., De Seze, J., Debouverie, M., Depaz, R., Derache, N., Divio, L., Douay, X., Dulau, C., Durand-Dubief, F., Edan, G., Elias, Z., Fagniez, O., Faucher, M., Faucheux, J.-M., Fournier, M., Gagneux-Brunon, A., Gaida, P., Galli, P., Gallien, P., Gaudelus, J., Gault, D., Gayou, A., Genevray, M., Gentil, A., Gere, J., Gignoux, L., Giroux, M., Givron, P., Gout, O., Grimaud, J., Guennoc, A.-M., Hadhoum, N., Hautecoeur, P., Heinzlef, O., Jaeger, M., Jeannin, S., Kremer, L., Kwiatkowski, A., Labauge, P., Labeyrie, C., Lachaud, S., Laffont, I., Lanctin-Garcia, C., Lannoy, J., Lanotte, L., Laplaud, D., Latombe, D., Lauxerois, M., Le Page, E., Lebrun-Frenay, C., Lejeune, P., Lejoyeux, P., Lemonnier, B., Leray, E., Loche, C.-M., Louapre, C., Lubetzki, C., Maarouf, A., Mada, B., Magy, L., Maillart, E., Manchon, E., Marignier, R., Marque, P., Mathey, G., Maurousset, A., Mekies, C., Merienne, M., Michel, L., Milor, A.-M., Moisset, X., Montcuquet, A., Moreau, T., Morel, N., Moussa, M., Naudillon, J.-P., Normand, M., Olive, P., Ouallet, J.-C., Outteryck, O., Pacault, C., Papeix, C., Patry, I., Peaureaux, D., Pelletier, J., Pichon, B., Pittion, S., Planque, E., Pouget, M.-C., Pourcher, V., Radot, C., Robert, I., Rocher, F., Ruet, A., Saint-Val, C., Salle, J.-Y., Salmon, A., Sartori, E., Schaeffer, S., Stankhof, B., Taithe, F., Thouvenot, E., Tizon, C., Tourbah, A., Tourniaire, P., Vaillant, M., Vermersch, P., Vidil, S., Wahab, A., Warter, M.-H., Wiertlewski, S., Wiplosz, B., Wittwer, B., Zaenker, C., Zephir, H., Lebrun, C., and Vukusic, S.
- Published
- 2019
- Full Text
- View/download PDF
8. Should we broaden indications for anti-JCV antibody tests in multiple sclerosis patients? YES
- Author
-
Wiertlewski, S.
- Published
- 2017
- Full Text
- View/download PDF
9. Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients
- Author
-
Balloy, G., Pelletier, J., Suchet, L., Lebrun, C., Cohen, M., Vermersch, P., Zephir, H., Duhin, E., Gout, O., Deschamps, R., Le Page, E., Edan, G., Labauge, P., Carra-Dallieres, C., Rumbach, L., Berger, E., Lejeune, P., Devos, P., N’Kendjuo, J.-B., Coustans, M., Auffray-Calvier, E., Daumas-Duport, B., Michel, L., Lefrere, F., Laplaud, D. A., Brosset, C., Derkinderen, P., de Seze, J., Wiertlewski, S., and On behalf of the Société Francophone de la Sclérose en Plaques
- Published
- 2018
- Full Text
- View/download PDF
10. Natalizumab and drug holiday in clinical practice: An observational study in very active relapsing remitting Multiple Sclerosis patients
- Author
-
Kerbrat, A., Le Page, E., Leray, E., Anani, T., Coustans, M., Desormeaux, C., Guiziou, C., Kassiotis, P., Lallement, F., Laplaud, D., Diraison, P., Rouhart, F., Sartori, E., Wardi, R., Wiertlewski, S., and Edan, G.
- Published
- 2011
- Full Text
- View/download PDF
11. Multiple sclerosis and access to healthcare in the Pays de la Loire region: Preliminary study based on 130 self-applied double questionnaires
- Author
-
Le Fort, M., Wiertlewski, S., Bernard, I., Bernier, C., Bonnemain, B., Moreau, C., Nicolas-Chouet, C., Pavillon, T., Tanguy, E., Villard, A., Bertout, P., Bodic, P., Desjobert, S., Kieny, P., Lejeune, P., and Lombrail, P.
- Published
- 2011
- Full Text
- View/download PDF
12. Cost-utility of oral methylprednisolone in the treatment of multiple sclerosis relapses: Results from the COPOUSEP trial
- Author
-
Michel, M., primary, Le Page, E., additional, Laplaud, D.A., additional, Wardi, R., additional, Lebrun, C., additional, Zagnoli, F., additional, Wiertlewski, S., additional, Coustans, M., additional, Edan, G., additional, Chevreul, K., additional, Veillard, D., additional, Lallement, F., additional, Cohen, M., additional, Blanchard, C., additional, Sartori, E., additional, Demarco, O., additional, Rouhart, F., additional, Papeix, C., additional, Taurin, G., additional, Anani, T., additional, Kassiotis, P., additional, Hamon, C., additional, Lester, M.A., additional, and Merienne, M., additional
- Published
- 2022
- Full Text
- View/download PDF
13. Improving the decision to switch from first to second-line therapy in MS: a dynamic scoring system
- Author
-
Sabathe, C., Casey, Romain, Vukusic, S., Leray, Emmanuelle, Mathey, G., de Seze, J., Ciron, J., Wiertlewski, S., Ruet, A., Pelletier, J., Zephir, H., Michel, L., Lebrun-Frenay, C., Moisset, X., Thouvenot, Eric, Camdessanche, J. -P., Bakchine, Serge, Stankoff, B., Al Khedr, A., Cabre, P., Maillart, E., Berger, E., Heinzlef, O., Hankiewicz, K., Moreau, T., Gout, O., Bourre, B., Wahab, A., Labauge, Pierre, Montcuquet, A., Defer, G., Maurousset, A., Maubeuge, N., Dalia, D. Boulos, Ben Nasr, H., Nifle, C., Casez, O., Laplaud, D. -A., Foucher, yohann, MethodS in Patients-centered outcomes and HEalth ResEarch (SPHERE), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques, Université de Nantes (UN)-Université de Nantes (UN), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hospices Civils de Lyon (HCL), Recherche en Pharmaco-épidémiologie et Recours aux Soins (REPERES), Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP), École des Hautes Études en Santé Publique [EHESP] (EHESP), Adaptation, mesure et évaluation en santé. Approches interdisciplinaires (APEMAC), Université de Lorraine (UL), Service de neurologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), CHU Strasbourg, CIC Strasbourg (Centre d’Investigation Clinique Plurithématique (CIC - P) ), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Nouvel Hôpital Civil de Strasbourg-Hôpital de Hautepierre [Strasbourg], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre hospitalier universitaire de Nantes (CHU Nantes), Centre de Recherche en Transplantation et Immunologie (U1064 Inserm - CRTI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Bordeaux (UB), Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale (U1215 Inserm - UB), Université de Bordeaux (UB)-Institut François Magendie-Institut National de la Santé et de la Recherche Médicale (INSERM), CIC Bordeaux, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital de la Timone [CHU - APHM] (TIMONE), Lille Neurosciences & Cognition - U 1172 (LilNCog), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Microenvironment, Cell Differentiation, Immunology and Cancer (MICMAC), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Nice [Cimiez], Hôpital Cimiez [Nice] (CHU), CHU Clermont-Ferrand, Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Institut de Génomique Fonctionnelle (IGF), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Centre Hospitalier Universitaire de Reims (CHU Reims), Institut du Cerveau = Paris Brain Institute (ICM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), CHU Amiens-Picardie, CHU de la Martinique [Fort de France], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de Neurologie [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), CHI Poissy-Saint-Germain, Centre Hospitalier de Saint-Denis [Ile-de-France], Centre d'épidémiologie des populations (CEP), Université de Bourgogne (UB)-Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER-UNICANCER, Fondation Ophtalmologique Adolphe de Rotschild, CHU Rouen, Normandie Université (NU), CHU Henri Mondor [Créteil], CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), CHU Limoges, CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), INSERM CIC 0802 (INSERM - CHU de Poitiers), Université de Poitiers-Centre hospitalier universitaire de Poitiers (CHU Poitiers)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Hémostase, Inflammation, Thrombose (HITH - U1176 Inserm - CHU Bicêtre), Institut National de la Santé et de la Recherche Médicale (INSERM)-AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre)-Université Paris-Saclay, Hôpital Sud Francilien Corbeil Essonne, Centre de Référence des Maladies Auto-Inflammatoires et des Amyloses [CH Versailles] (CeRéMAIA - Hôpital André Mignot), Centre Hospitalier de Versailles André Mignot (CHV), Laboratoire de Génétique Chromosomique [CHU de Grenoble], CHU Grenoble, Agence Nationale de la Recherche French National Research Agency (ANR) uropean Commission [ANR-10COHO-002], Fond de dotation de l'Universite de Nantes, Foundation EDMUS, ANR-10-COHO-0002,OFSEP,Observatoire Français de la Sclérose en Plaques(2010), Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques, Centre de recherche en neurosciences de Lyon (CRNL), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Strasbourg (UNISTRA)-Hôpital de Hautepierre [Strasbourg]-Nouvel Hôpital Civil de Strasbourg, CHU Toulouse [Toulouse], Physiopathologie de la Plasticité Neuronale (Neurocentre Magendie - U1215 Inserm), Lille Neurosciences & Cognition - U 1172 (LilNCog (ex-JPARC)), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Université de Montpellier (UM)-Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Montpellier 2 - Sciences et Techniques (UM2)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), CHU Henri Mondor, Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre hospitalier universitaire de Poitiers (CHU Poitiers)-Université de Poitiers, Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
- Subjects
[SDV]Life Sciences [q-bio] ,ComputingMilieux_MISCELLANEOUS - Abstract
International audience; Meeting Abstract 035
- Published
- 2021
- Full Text
- View/download PDF
14. Efficacy of L-carnitine in the treatment of fatigue in multiple sclerosis (FACTSEP): EP2133
- Author
-
Ouallet, J.-C., Laplaud, D., Wiertlewski, S., Lanctin-Garcia, C., Lebrun-Frenay, C., Cohen, M., Debouverie, M., Pittion-Vouyovitch, S., Cabre, P., Jeannin, S., Brassat, D., Chêne, G., Asselineau, J., Saubusse, A., Chateauraynaud, J., Djigo, D., and Brochet, B.
- Published
- 2014
15. Mycophenolate mofetil in multiple sclerosis: a multicentre retrospective study on 344 patients
- Author
-
Michel, L, Vukusic, S, De Seze, J, Ducray, F, Ongagna, J C, Lefrère, F, Jacq-Foucher, M, Confavreux, C, Wiertlewski, S, and Laplaud, D A
- Published
- 2014
- Full Text
- View/download PDF
16. High dimensional single-cell profiling identifies NK-like CD8+T cells with high cytotoxic properties that are the reservoir of clonal cells related to disease activity in multiple sclerosis
- Author
-
Dugast, E., Vogel, I., Kervagoet, E., Monvoisin, C., Garcia, A., Morille, J., Shah, S., Jacq-Foucher, M., Moyon, M., Le Frere, F., Wiertlewski, S., Karin Tarte, Nicot, A., Michel, L., Gourraud, P-A, Renand, A., Berthelot, L., Laplaud, D-A, Centre de Recherche en Transplantation et Immunologie (U1064 Inserm - CRTI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Microenvironment, Cell Differentiation, Immunology and Cancer (MICMAC), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre hospitalier universitaire de Nantes (CHU Nantes), Université de Rennes 1 (UR1), and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )
- Subjects
[SDV]Life Sciences [q-bio] ,ComputingMilieux_MISCELLANEOUS - Abstract
International audience
- Published
- 2021
17. Activated Tfh1 cells infiltrate the cerebrospinal fluid in early multiple sclerosis
- Author
-
Morille, J., Mandon, M., Rodriguez, S., Garcia, A., Wiertlewski, S., Berthelot, L., Karin Tarte, Delaloy, C., Ame, P., Laplaud, D-A, Michel, L., Centre hospitalier universitaire de Nantes (CHU Nantes), CHU Pontchaillou [Rennes], Microenvironment, Cell Differentiation, Immunology and Cancer (MICMAC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CIC - Nantes, Université de Nantes (UN)-IFR26-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), and Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
[SDV]Life Sciences [q-bio] ,ComputingMilieux_MISCELLANEOUS - Abstract
International audience; Meeting Abstract 025
- Published
- 2021
18. Eur J Neurol
- Author
-
Veillard, D. (David), Baumstarck, K. (Karine), Edan, G. (Gilles), Debouverie, M. (Marc), Wiertlewski, S. (Sandrine), De Sèze, J. (Jérôme), Clavelou, P. (Pierre), Pelletier, J. (Jean), Verny, C. (Christophe), Chauvin, K. (Karine), Cosson, M. (Marie Elisabeth) E. (E), Loundou, A. (Anderson), and Auquier, P. (Pascal)
- Subjects
Aucun - Abstract
BACKGROUND AND PURPOSE: Patients with a chronic illness, such as multiple sclerosis (MS), and their natural caregivers have a specific experience of healthcare and health services. These experiences need to be assessed to evaluate the quality of care. Our objective was to develop a French-language questionnaire to evaluate the quality of care as experienced by MS patients and their natural caregivers. METHODS: Eligible patients had been diagnosed with MS according to the McDonald criteria. Eligible caregivers were individuals designated by the patients. The MusiCare questionnaire was developed in two standard phases: (i) item generation, based on interviews with patients and caregivers; and (ii) validation, consisting of validity, reliability, external validity, reproducibility, and responsiveness measures. RESULTS: In total, 1088 patients (n = 660) and caregivers (n = 488) were recruited. The initial 64-item version of MusiCare was administered to a random subsample (n = 748). The validation process generated a 35-item questionnaire. Internal consistency and scalability were satisfactory. Testing of the external validity revealed expected associations between MusiCare scores and sociodemographic and clinical data. The questionnaire showed good reproducibility and responsiveness. CONCLUSIONS: The availability of a reliable and validated French-language self-report questionnaire probing the experience of the quality of care for MS will allow the feedback of patients and caregivers to be incorporated into a continuous healthcare quality-improvement strategy.
- Published
- 2021
19. Augmentation du risque de poussée de sclérose en plaques après stimulation ovarienne pour fécondation in vitro
- Author
-
Laplaud, D.-A., Lefrère, F., Leray, E., Barrière, P., and Wiertlewski, S.
- Published
- 2007
- Full Text
- View/download PDF
20. A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort
- Author
-
Outteryck, O., Ongagna, J. C., Brochet, B., Rumbach, L., Lebrun-Frenay, C., Debouverie, M., Zéphir, H., Ouallet, J. C., Berger, E., Cohen, M., Pittion, S., Laplaud, D., Wiertlewski, S., Cabre, P., Pelletier, J., Rico, A., Defer, G., Derache, N., Camu, W., Thouvenot, E., Moreau, T., Fromont, A., Tourbah, A., Labauge, P., Castelnovo, G., Clavelou, P., Casez, O., Hautecoeur, P., Papeix, C., Lubetzki, C., Fontaine, B., Couturier, N., Bohossian, N., Clanet, M., Vermersch, P., de Sèze, J., and Brassat, D.
- Published
- 2014
- Full Text
- View/download PDF
21. Myélite aiguë transverse idiopathique : application des nouveaux critères diagnostiques à une cohorte de 17 patients
- Author
-
Lanctin, C., Wiertlewski, S., Moreau, C., Verny, C., Derkinderen, P., Damier, P., and Dubas, F.
- Published
- 2006
- Full Text
- View/download PDF
22. SMILE: a predictive model for Scoring the severity of relapses in MultIple scLErosis
- Author
-
Lejeune, F., primary, Chatton, A., additional, Laplaud, D.-A., additional, Le Page, E., additional, Wiertlewski, S., additional, Edan, G., additional, Kerbrat, A., additional, Veillard, D., additional, Hamonic, S., additional, Jousset, N., additional, Le Frère, F., additional, Ouallet, J.-C., additional, Brochet, B., additional, Ruet, A., additional, Foucher, Y., additional, and Michel, Laure, additional
- Published
- 2020
- Full Text
- View/download PDF
23. Response to Finsterer and colleagues on ‘Prospective studies on the efficacy of rituximab for myasthenia gravis are warranted’
- Author
-
Dos Santos, A., primary, Pereon, Y., additional, Wiertlewski, S., additional, and Magot, A., additional
- Published
- 2020
- Full Text
- View/download PDF
24. Efficacy and safety of rituximab in myasthenia gravis: a French multicentre real‐life study
- Author
-
Dos Santos, A., primary, Noury, J. ‐B., additional, Genestet, S., additional, Nadaj‐Pakleza, A., additional, Cassereau, J., additional, Baron, C., additional, Videt, D., additional, Michel, L., additional, Pereon, Y., additional, Wiertlewski, S., additional, and Magot, A., additional
- Published
- 2020
- Full Text
- View/download PDF
25. High-Dimensional Profiling of Single Memory CD8+T cells Reveals a Specific Pattern in Multiple Sclerosis Patients
- Author
-
Dugast, E., Vogel, I., Renand, A., Garcia, A., Nicol, B., Morille, J, Jacq-Foucher, M., Jousset, N., Le Frère, F., Wiertlewski, S., Nicot, A., Michel, L., Berthelot, L., Gourraud, P.-A, Nataf, S., Tarte, K., Laplaud, D.-A, Centre de Recherche en Transplantation et Immunologie (U1064 Inserm - CRTI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Institut de transplantation urologie-néphrologie (ITUN), Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes), CIC - Nantes, Université de Nantes (UN)-IFR26-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de neurologie [Nantes], Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Hôpital Guillaume-et-René-Laennec [Saint-Herblain], Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM), Microenvironnement et cancer (MiCa), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Le Bihan, Sylvie, and Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hospices Civils de Lyon (HCL)
- Subjects
[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology ,ComputingMilieux_MISCELLANEOUS ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology - Abstract
International audience
- Published
- 2019
26. Fistules durales à drainage veineux cortical: Une cause rare de démence curable
- Author
-
Magot, A., Desal, H., Wiertlewski, S., Houdart, E., Vercelletto, M., Al Hammad Ibrahim, M., and Guillon, B.
- Published
- 2004
- Full Text
- View/download PDF
27. EP.30Usefulness of extraocular muscle imagery in the diagnosis of myasthenia gravis and chronic progressive external ophthalmoplegia
- Author
-
Lepetit, M., primary, Toulgoat, F., additional, Wiertlewski, S., additional, Péréon, Y., additional, and Magot, A., additional
- Published
- 2019
- Full Text
- View/download PDF
28. Immunization and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society
- Author
-
Lebrun, C., primary, Vukusic, S., additional, Abadie, V., additional, Achour, C., additional, Ader, F., additional, Alchaar, H., additional, Alkhedr, A., additional, Andreux, F., additional, Androdias, G., additional, Arjmand, R., additional, Audoin, B., additional, Audry, D., additional, Aufauvre, D., additional, Autreaux, C., additional, Ayrignac, X., additional, Bailbe, M., additional, Benazet, M., additional, Bensa, C., additional, Bensmail, D., additional, Berger, E., additional, Bernady, P., additional, Bertagna, Y., additional, Biotti, D., additional, Blanchard-Dauphin, A., additional, Bonenfant, J., additional, Bonnan, M., additional, Bonnemain, B., additional, Borgel, F., additional, Botelho-Nevers, E., additional, Boucly, S., additional, Bourre, B., additional, Boutière, C., additional, Branger, P., additional, Brassat, D., additional, Bresch, S., additional, Breuil, V., additional, Brochet, B., additional, Brugeilles, H., additional, Bugnon, P., additional, Cabre, P., additional, Camdessanché, J.-P., additional, Carra-Dalière, C., additional, Casez, O., additional, Chamouard, J.-M., additional, Chassande, B., additional, Chataignier, P., additional, Chbicheb, M., additional, Chenet, A., additional, Ciron, J., additional, Clavelou, P., additional, Cohen, M., additional, Colamarino, R., additional, Collongues, N., additional, Coman, I., additional, Corail, P.-R., additional, Courtois, S., additional, Coustans, M., additional, Creange, A., additional, Creisson, E., additional, Daluzeau, N., additional, Davenas, C., additional, De Seze, J., additional, Debouverie, M., additional, Depaz, R., additional, Derache, N., additional, Divio, L., additional, Douay, X., additional, Dulau, C., additional, Durand-Dubief, F., additional, Edan, G., additional, Elias, Z., additional, Fagniez, O., additional, Faucher, M., additional, Faucheux, J.-M., additional, Fournier, M., additional, Gagneux-Brunon, A., additional, Gaida, P., additional, Galli, P., additional, Gallien, P., additional, Gaudelus, J., additional, Gault, D., additional, Gayou, A., additional, Genevray, M., additional, Gentil, A., additional, Gere, J., additional, Gignoux, L., additional, Giroux, M., additional, Givron, P., additional, Gout, O., additional, Grimaud, J., additional, Guennoc, A.-M., additional, Hadhoum, N., additional, Hautecoeur, P., additional, Heinzlef, O., additional, Jaeger, M., additional, Jeannin, S., additional, Kremer, L., additional, Kwiatkowski, A., additional, Labauge, P., additional, Labeyrie, C., additional, Lachaud, S., additional, Laffont, I., additional, Lanctin-Garcia, C., additional, Lannoy, J., additional, Lanotte, L., additional, Laplaud, D., additional, Latombe, D., additional, Lauxerois, M., additional, Le Page, E., additional, Lebrun-Frenay, C., additional, Lejeune, P., additional, Lejoyeux, P., additional, Lemonnier, B., additional, Leray, E., additional, Loche, C.-M., additional, Louapre, C., additional, Lubetzki, C., additional, Maarouf, A., additional, Mada, B., additional, Magy, L., additional, Maillart, E., additional, Manchon, E., additional, Marignier, R., additional, Marque, P., additional, Mathey, G., additional, Maurousset, A., additional, Mekies, C., additional, Merienne, M., additional, Michel, L., additional, Milor, A.-M., additional, Moisset, X., additional, Montcuquet, A., additional, Moreau, T., additional, Morel, N., additional, Moussa, M., additional, Naudillon, J.-P., additional, Normand, M., additional, Olive, P., additional, Ouallet, J.-C., additional, Outteryck, O., additional, Pacault, C., additional, Papeix, C., additional, Patry, I., additional, Peaureaux, D., additional, Pelletier, J., additional, Pichon, B., additional, Pittion, S., additional, Planque, E., additional, Pouget, M.-C., additional, Pourcher, V., additional, Radot, C., additional, Robert, I., additional, Rocher, F., additional, Ruet, A., additional, Saint-Val, C., additional, Salle, J.-Y., additional, Salmon, A., additional, Sartori, E., additional, Schaeffer, S., additional, Stankhof, B., additional, Taithe, F., additional, Thouvenot, E., additional, Tizon, C., additional, Tourbah, A., additional, Tourniaire, P., additional, Vaillant, M., additional, Vermersch, P., additional, Vidil, S., additional, Wahab, A., additional, Warter, M.-H., additional, Wiertlewski, S., additional, Wiplosz, B., additional, Wittwer, B., additional, Zaenker, C., additional, and Zephir, H., additional
- Published
- 2019
- Full Text
- View/download PDF
29. CD161 intermediate expression defines a novel activated, inflammatory and pathogenic subset of CD8+ T cells involved in multiple sclerosis
- Author
-
Nicol, B., Salou, M., Vogel, I., Garcia, A., Dugast, E., Morille, J., Killens, S., Charpentier, E., Donnant, A., Nedellec, S., Jacq-Foucher, M., Le Frère, F., Wiertlewski, S., Bourreille, A., Brouard, S., Michel, L., David, L., Gourraud, P.-A, Degauque, N., Nicot, A., Berthelot, L., Laplaud, David, Centre de Recherche en Transplantation et Immunologie (U1064 Inserm - CRTI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Institut du Cerveau = Paris Brain Institute (ICM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Unité de recherche de l'institut du thorax (ITX-lab), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Plateforme MicroPicell [Nantes], Université de Nantes (UN), Centre hospitalier universitaire de Nantes (CHU Nantes), Service de neurologie [Nantes], Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Hôpital Guillaume-et-René-Laennec [Saint-Herblain], Service d'hépato-gastroentérologie [CHU Nantes], Structure fédérative de recherche François Bonamy (SFR François Bonamy), Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche en Santé de l'Université de Nantes (IRS-UN), Le Bihan, Sylvie, Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), and unité de recherche de l'institut du thorax UMR1087 UMR6291 (ITX)
- Subjects
[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology ,ComputingMilieux_MISCELLANEOUS ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology - Abstract
International audience
- Published
- 2017
30. Gene-expression analysis of blood memory CD8+T cells at the single-cell level reveals a specific pattern of clonally expanded cells in multiple sclerosis patients
- Author
-
Dugast, E., Vogel, I., Garcia, A., Nicol, B., Morille, J., Jacq-Foucher, M., Jousset, N., Le Frere, F., Wiertlewski, S., Karin Tarte, Nicot, A., Michel, L., Berthelot, L., Gourraud, P. -A, Laplaud, D. -A, Centre de Recherche en Transplantation et Immunologie (U1064 Inserm - CRTI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Centre hospitalier universitaire de Nantes (CHU Nantes), Microenvironment, Cell Differentiation, Immunology and Cancer (MICMAC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), and Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )
- Subjects
[SDV.CAN]Life Sciences [q-bio]/Cancer ,ComputingMilieux_MISCELLANEOUS - Abstract
International audience
- Published
- 2017
- Full Text
- View/download PDF
31. Neuromyélite optique de Devic et patients à haut risqué : enquête rétrospective nationale
- Author
-
Collongues, N., Marignier, R., Zéphir, H., Papeix, C., Blanc, F., Tchikviladzé, M., Ritleng, C., Outteryck, O., Vukusic, S., Fleury, M., Mignot, C., Brassat, D., Clanet, M., Milh, M., Ruet, A., Lebrun-Frenay, C., Camu, W., Debouverie, M., Créange, A., Moreau, T., Labauge, P., Castelnovo, G., Edan, G., Lepage, E., Defer, G., Barroso, B., Thouvenot, E., Heinzlef, O., Gout, O., Rodriguez, D., Augustin, J., Wiertlewski, S., Laplaud, D., Borgel, F., Slassi, I., Berroir, S., Tourniaire, P., Grimaud, J., Brochet, B., Vermersch, P., Confavreux, C., and de Sèze, J.
- Published
- 2009
- Full Text
- View/download PDF
32. Sécurité, tolérance et efficacité de la pravastatine dans la sclérose en plaques rémittente - STEP : une étude pilote randomisée en double aveugle contre placebo
- Author
-
Laplaud, D.-A., Lefrere, F., Auffray-Calvier, E., Guillemot, L., Edan, G., Le Page, E., Nguyen, J.-M., Soulillou, J.-P., Damier, P., and Wiertlewski, S.
- Published
- 2009
- Full Text
- View/download PDF
33. Efficacité comparée du Teriflunomide et du Dimethyl-Fumarate : une étude observationnelle française multicentrique
- Author
-
Laplaud, D.-A., primary, Barbin, L., additional, Casey, R., additional, Debouverie, M., additional, Vukusic, S., additional, Labauge, P., additional, Brassat, D., additional, Wiertlewski, S., additional, De Seze, J., additional, Edan, G., additional, Brochet, B., additional, Moreau, T., additional, Berger, E., additional, Clavelou, P., additional, Castelnovo, G., additional, Ciron, J., additional, Pelletier, J., additional, Bourre, B., additional, Lubetzki, C., additional, Al Khedr, A., additional, Vermersch, P., additional, Lebrun-Frenay, C., additional, Defer, G., additional, Tourbah, A., additional, Camdessanche, J.-P., additional, Stankoff, B., additional, Labeyrie, C., additional, Patry, I., additional, Creange, A., additional, Gout, O., additional, Heinzlef, O., additional, Casez, O., additional, Magy, L., additional, Guennoc, A.-M., additional, De Broucker, T., additional, Nifle, C., additional, Dupel-Pottier, C., additional, Leray, E., additional, Rollot, F., additional, and Foucher, Y., additional
- Published
- 2018
- Full Text
- View/download PDF
34. Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS
- Author
-
Lavie, Caroline, primary, Rollot, Fabien, additional, Durand-Dubief, Françoise, additional, Marignier, Romain, additional, Ionescu, Iuliana, additional, Casey, Romain, additional, Moreau, Thibault, additional, Tourniaire, Patricia, additional, Hutchinson, Michael, additional, D’Hooghe, Marie Béatrice, additional, Laplaud, David-Axel, additional, Clavelou, Pierre, additional, De Sèze, Jérôme, additional, Debouverie, Marc, additional, Brassat, David, additional, Pelletier, Jean, additional, Lebrun-Frenay, Christine, additional, Le Page, Emmanuelle, additional, Castelnovo, Giovanni, additional, Berger, Eric, additional, Hautecoeur, Patrick, additional, Heinzlef, Olivier, additional, Durelli, Luca, additional, Clerico, Marinella, additional, Trojano, Maria, additional, Patti, Francesco, additional, Vukusic, Sandra, additional, Alpérovitch, A., additional, Carton, H., additional, d’Hooghe, M.B., additional, Hommes, O., additional, Hutchinson, M., additional, Adeleine, P., additional, Biron, A., additional, Cortinovis-Tourniaire, P., additional, Grimaud, J., additional, Hours, M., additional, Moreau, T., additional, Vukusic, S., additional, Confavreux, C., additional, Chauplannaz, G., additional, Latombe, D., additional, Clanet, M., additional, Lau, G., additional, Rumbach, L., additional, Goas, J.Y., additional, Rouhart, F., additional, Mazingue, A., additional, Roullet, E., additional, Madigand, M., additional, Hautecoeur, P., additional, Brunet, P., additional, Edan, G., additional, Allaire, C., additional, Riffault, G., additional, Leche, J., additional, Benoit, T., additional, Simonin, C., additional, Ziegler, F., additional, Baron, J.C., additional, Rivrain, Y., additional, Dumas, R., additional, Loche, D., additional, Bourrin, J.C., additional, Huttin, B., additional, Delisse, B., additional, Gibert, I., additional, Boulay, C., additional, Verceletto, M., additional, Durand, G., additional, Bonneviot, G., additional, Gil, R., additional, Hedreville, M.A., additional, Belair, C., additional, Poitevin, R.J., additional, Devoize, J.L., additional, Wyremblewski, P., additional, Delestre, F., additional, Setiey, A., additional, Comi, G., additional, Filippi, M., additional, Ghezzi, A., additional, Martinelli, V., additional, Rossi, P., additional, Zaffaroni, M., additional, Tola, M.R., additional, Amato, M.P., additional, Fioretti, C., additional, Meucci, G., additional, Inglese, M., additional, Mancardi, G.L., additional, Gambi, D., additional, Thomas, A., additional, Cavazzuti, M., additional, Citterio, A., additional, Heltberg, A., additional, Hansen, H.J., additional, Fernandez, O., additional, Romero, F., additional, Arbizu, T., additional, Hernandez, J.J., additional, De Andres de Frutos, C., additional, Geffner Sclarky, D., additional, Aladro Benito, Y., additional, Reyes Yanes, P., additional, Aguilar, M, additional, Burguera, J.A., additional, Yaya, R., additional, Bonakim Dib, W., additional, Arzua-Mouronte, D., additional, Sindic, C.J.M., additional, Medaer, R., additional, Roose, H., additional, Geens, K.M.J., additional, Guillaume, D., additional, Van Zandycke, M., additional, Janssens, J., additional, Cornette, M., additional, Mol, L., additional, Weilbach, F., additional, Flachenecker, P., additional, Hartung, H.P., additional, Haas, J., additional, Tendolkar, I., additional, Sindrn, E., additional, Kölmel, H.W., additional, Reichel, D., additional, Rauch, M., additional, Preuss, S., additional, Poser, S., additional, Mauch, E., additional, Strausser-Fuchs, S., additional, Kolleger, H., additional, Hawkins, S., additional, Howell, S.J.L., additional, Rees, J.E., additional, Thompson, A., additional, Johnson, M., additional, Boggild, M., additional, Gregory, R.P., additional, Bates, D., additional, Bone, I., additional, Polman, C., additional, Frequin, S., additional, Jongen, P., additional, Correia de Sa, J., additional, Rio, M.E., additional, Huber, S., additional, Lechner-Scott, J., additional, Kappos, L., additional, Ionescu, I., additional, Cornu, C., additional, El-Etr, M., additional, Baulieu, E.E., additional, Schumacher, M, additional, Miller, D.H., additional, Pugeat, M., additional, d’Archangues, C., additional, Conard, J., additional, Ménard, J., additional, Sitruk-Ware, R., additional, Pelissier, C., additional, Dat, S., additional, Belaïsch-Allard, J., additional, Athéa, N., additional, Büschsenschutz, D., additional, Lyon-Caen, O., additional, Gonsette, R., additional, Boissel, J.P., additional, Ffrench, P., additional, Durand-Dubief, F., additional, Cotton, F., additional, Pachai, C., additional, Bracoud, L., additional, Androdias, G., additional, Marignier, R., additional, Laplaud, D.A., additional, Wiertlewski, S., additional, Lanctin-Garcia, C., additional, Couvreur, G., additional, Madinier, G., additional, Clavelou, P., additional, Taithe, F., additional, Aufauvre, D., additional, Guy, N., additional, Ferrier, A., additional, De Sèze, J., additional, Collongues, N., additional, Debouverie, M., additional, Viala, F., additional, Brassat, D., additional, Gerdelat-Mas, A., additional, Henry, P., additional, Pelletier, J., additional, Rico-Lamy, A., additional, Lebrun-Frenay, C., additional, Lepage, E., additional, Deburghraeve, V., additional, Castelnovo, G., additional, Berger, E., additional, Blondiau, M., additional, Heinzlef, O., additional, Coustans, M., additional, Clerc, C., additional, Rieu, L., additional, Lauxerois, M., additional, Hinzelin, G., additional, Ouallet, J.C., additional, Minier, D., additional, Vion, P., additional, Gromaire-Fayolle, N., additional, Derache, N., additional, Thouvenot, E., additional, Sallansonnet-Froment, M., additional, Tourniaire, P., additional, Toureille, L., additional, Borgel, F., additional, Stankoff, B., additional, Moroianu, C., additional, Guennoc, A.M., additional, Tournier-Gervason, C.L., additional, Peysson, S., additional, Trojano, M., additional, Patti, F., additional, D’Amico, E., additional, Motti, L., additional, Durelli, L., additional, and Tavella, A., additional
- Published
- 2018
- Full Text
- View/download PDF
35. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
- Author
-
Kappos, L., Bar-Or, A., Cree, B. A. C., Fox, R. J., Giovannoni, G., Gold, R., Vermersch, P., Arnold, D. L., Arnould, S., Scherz, T., Wolf, C., Wallstrom, E., Dahlke, F., Achiron, A., Achtnichts, L., Agan, K., Akman-Demir, G., Allen, A. B., Antel, J. P., Antiguedad, A. R., Apperson, M., Applebee, A. M., Ayuso, G. I., Baba, M., Bajenaru, O., Balasa, R., Balci, B. P., Barnett, M., Bass, A., Becker, V. U., Bejinariu, M., Bergh, F. T., Bergmann, A., Bernitsas, E., Berthele, A., Bhan, V., Bischof, F., Bjork, R. J., Blevins, G., Boehringer, M., Boerner, T., Bonek, R., Bowen, J. D., Bowling, A., Boyko, A. N., Boz, C., Bracknies, V., Braune, S., Brescia Morra, V., Brochet, B., Brola, W., Brownstone, P. K., Brozman, M., Brunet, D., Buraga, I., Burnett, M., Buttmann, M., Butzkueven, H., Cahill, J., Calkwood, J. C., Camu, W., Cascione, M., Castelnovo, G., Centonze, D., Cerqueira, J., Chan, A., Cimprichova, A., Cohan, S., Comi, G., Conway, J., Cooper, J. A., Corboy, J., Correale, J., Costell, B., Cottrell, D. A., Coyle, P. K., Craner, M., Cui, L., Cunha, L., Czlonkowska, A., da Silva, A. M., de Sa, J., de Seze, J., Debouverie, M., Debruyne, J., Decoo, D., Defer, G., Derfuss, T., Deri, N. H., Dihenia, B., Dioszeghy, P., Donath, V., Dubois, B., Duddy, M., Duquette, P., Edan, G., Efendi, H., Elias, S., Emrich, P. J., Estruch, B. C., Evdoshenko, E. P., Faiss, J., Fedyanin, A. S., Feneberg, W., Fermont, J., Fernandez, O. F., Ferrer, F. C., Fink, K., Ford, H., Ford, C., Francia, A., Freedman, M., Frishberg, B., Galgani, S., Garmany, G. P., Gehring, K., Gitt, J., Gobbi, C., Goldstick, L. P., Gonzalez, R. A., Grandmaison, F., Grigoriadis, N., Grigorova, O., Grimaldi, L. M. E., Gross, J., Gross-Paju, K., Gudesblatt, M., Guillaume, D., Haas, J., Hancinova, V., Hancu, A., Hardiman, O., Harmjanz, A., Heidenreich, F. R., Hengstman, G. J. D., Herbert, J., Herring, M., Hodgkinson, S., Hoffmann, O. M., Hofmann, W. E., Honeycutt, W. D., Hua, L. H., Huang, D., Huang, Y., Hupperts, R., Imre, P., Jacobs, A. K., Jakab, G., Jasinska, E., Kaida, K., Kalnina, J., Kaprelyan, A., Karelis, G., Karussis, D., Katz, A., Khabirov, F. A., Khatri, B., Kimura, T., Kister, I., Kizlaitiene, R., Klimova, E., Koehler, J., Komatineni, A., Kornhuber, A., Kovacs, K., Koves, A., Kozubski, W., Krastev, G., Krupp, L. B., Kurca, E., Lassek, C., Laureys, G., Lee, L., Lensch, E., Leutmezer, F., Li, H., Linker, R. A., Linnebank, M., Liskova, P., Llanera, C., Lu, J., Lutterotti, A., Lycke, J., Macdonell, R., Maciejowski, M., Maeurer, M., Magzhanov, R. V., Maida, E. -M., Malciene, L., Mao-Draayer, Y., Marfia, G. A., Markowitz, C., Mastorodimos, V., Matyas, K., Meca-Lallana, J., Merino, J. A. G., Mihetiu, I. G., Milanov, I., Miller, A. E., Millers, A., Mirabella, M., Mizuno, M., Montalban, X., Montoya, L., Mori, M., Mueller, S., Nakahara, J., Nakatsuji, Y., Newsome, S., Nicholas, R., Nielsen, A. S., Nikfekr, E., Nocentini, U., Nohara, C., Nomura, K., Odinak, M. M., Olsson, T., van Oosten, B. W., Oreja-Guevara, C., Oschmann, P., Overell, J., Pachner, A., Panczel, G., Pandolfo, M., Papeix, C., Patrucco, L., Pelletier, J., Piedrabuena, R., Pless, M., Polzer, U., Pozsegovits, K., Rastenyte, D., Rauer, S., Reifschneider, G., Rey, R., Rizvi, S. A., Robertson, D., Rodriguez, J. M., Rog, D., Roshanisefat, H., Rowe, V., Rozsa, C., Rubin, S., Rusek, S., Sacca, F., Saida, T., Salgado, A. V., Sanchez, V. E. F., Sanders, K., Satori, M., Sazonov, D. V., Scarpini, E. A., Schlegel, E., Schluep, M., Schmidt, S., Scholz, E., Schrijver, H. M., Schwab, M., Schwartz, R., Scott, J., Selmaj, K., Shafer, S., Sharrack, B., Shchukin, I. A., Shimizu, Y., Shotekov, P., Siever, A., Sigel, K. -O., Silliman, S., Simo, M., Simu, M., Sinay, V., Siquier, A. E., Siva, A., Skoda, O., Solomon, A., Stangel, M., Stefoski, D., Steingo, B., Stolyarov, I. D., Stourac, P., Strassburger-Krogias, K., Strauss, E., Stuve, O., Tarnev, I., Tavernarakis, A., Tello, C. R., Terzi, M., Ticha, V., Ticmeanu, M., Tiel-Wilck, K., Toomsoo, T., Tubridy, N., Tullman, M. J., Tumani, H., Turcani, P., Turner, B., Uccelli, A., Urtaza, F. J. O., Vachova, M., Valikovics, A., Walter, S., Van Wijmeersch, B., Vanopdenbosch, L., Weber, J. R., Weiss, S., Weissert, R., West, T., Wiendl, H., Wiertlewski, S., Wildemann, B., Willekens, B., Visser, L. H., Vorobeychik, G., Xu, X., Yamamura, T., Yang, Y. N., Yelamos, S. M., Yeung, M., Zacharias, A., Zelkowitz, M., Zettl, U., Zhang, M., Zhou, H., Zieman, U., Ziemssen, T., Bergmann A., Haas J., Mirabella M. (ORCID:0000-0002-7783-114X), Terzi M., Kappos, L., Bar-Or, A., Cree, B. A. C., Fox, R. J., Giovannoni, G., Gold, R., Vermersch, P., Arnold, D. L., Arnould, S., Scherz, T., Wolf, C., Wallstrom, E., Dahlke, F., Achiron, A., Achtnichts, L., Agan, K., Akman-Demir, G., Allen, A. B., Antel, J. P., Antiguedad, A. R., Apperson, M., Applebee, A. M., Ayuso, G. I., Baba, M., Bajenaru, O., Balasa, R., Balci, B. P., Barnett, M., Bass, A., Becker, V. U., Bejinariu, M., Bergh, F. T., Bergmann, A., Bernitsas, E., Berthele, A., Bhan, V., Bischof, F., Bjork, R. J., Blevins, G., Boehringer, M., Boerner, T., Bonek, R., Bowen, J. D., Bowling, A., Boyko, A. N., Boz, C., Bracknies, V., Braune, S., Brescia Morra, V., Brochet, B., Brola, W., Brownstone, P. K., Brozman, M., Brunet, D., Buraga, I., Burnett, M., Buttmann, M., Butzkueven, H., Cahill, J., Calkwood, J. C., Camu, W., Cascione, M., Castelnovo, G., Centonze, D., Cerqueira, J., Chan, A., Cimprichova, A., Cohan, S., Comi, G., Conway, J., Cooper, J. A., Corboy, J., Correale, J., Costell, B., Cottrell, D. A., Coyle, P. K., Craner, M., Cui, L., Cunha, L., Czlonkowska, A., da Silva, A. M., de Sa, J., de Seze, J., Debouverie, M., Debruyne, J., Decoo, D., Defer, G., Derfuss, T., Deri, N. H., Dihenia, B., Dioszeghy, P., Donath, V., Dubois, B., Duddy, M., Duquette, P., Edan, G., Efendi, H., Elias, S., Emrich, P. J., Estruch, B. C., Evdoshenko, E. P., Faiss, J., Fedyanin, A. S., Feneberg, W., Fermont, J., Fernandez, O. F., Ferrer, F. C., Fink, K., Ford, H., Ford, C., Francia, A., Freedman, M., Frishberg, B., Galgani, S., Garmany, G. P., Gehring, K., Gitt, J., Gobbi, C., Goldstick, L. P., Gonzalez, R. A., Grandmaison, F., Grigoriadis, N., Grigorova, O., Grimaldi, L. M. E., Gross, J., Gross-Paju, K., Gudesblatt, M., Guillaume, D., Haas, J., Hancinova, V., Hancu, A., Hardiman, O., Harmjanz, A., Heidenreich, F. R., Hengstman, G. J. D., Herbert, J., Herring, M., Hodgkinson, S., Hoffmann, O. M., Hofmann, W. E., Honeycutt, W. D., Hua, L. H., Huang, D., Huang, Y., Hupperts, R., Imre, P., Jacobs, A. K., Jakab, G., Jasinska, E., Kaida, K., Kalnina, J., Kaprelyan, A., Karelis, G., Karussis, D., Katz, A., Khabirov, F. A., Khatri, B., Kimura, T., Kister, I., Kizlaitiene, R., Klimova, E., Koehler, J., Komatineni, A., Kornhuber, A., Kovacs, K., Koves, A., Kozubski, W., Krastev, G., Krupp, L. B., Kurca, E., Lassek, C., Laureys, G., Lee, L., Lensch, E., Leutmezer, F., Li, H., Linker, R. A., Linnebank, M., Liskova, P., Llanera, C., Lu, J., Lutterotti, A., Lycke, J., Macdonell, R., Maciejowski, M., Maeurer, M., Magzhanov, R. V., Maida, E. -M., Malciene, L., Mao-Draayer, Y., Marfia, G. A., Markowitz, C., Mastorodimos, V., Matyas, K., Meca-Lallana, J., Merino, J. A. G., Mihetiu, I. G., Milanov, I., Miller, A. E., Millers, A., Mirabella, M., Mizuno, M., Montalban, X., Montoya, L., Mori, M., Mueller, S., Nakahara, J., Nakatsuji, Y., Newsome, S., Nicholas, R., Nielsen, A. S., Nikfekr, E., Nocentini, U., Nohara, C., Nomura, K., Odinak, M. M., Olsson, T., van Oosten, B. W., Oreja-Guevara, C., Oschmann, P., Overell, J., Pachner, A., Panczel, G., Pandolfo, M., Papeix, C., Patrucco, L., Pelletier, J., Piedrabuena, R., Pless, M., Polzer, U., Pozsegovits, K., Rastenyte, D., Rauer, S., Reifschneider, G., Rey, R., Rizvi, S. A., Robertson, D., Rodriguez, J. M., Rog, D., Roshanisefat, H., Rowe, V., Rozsa, C., Rubin, S., Rusek, S., Sacca, F., Saida, T., Salgado, A. V., Sanchez, V. E. F., Sanders, K., Satori, M., Sazonov, D. V., Scarpini, E. A., Schlegel, E., Schluep, M., Schmidt, S., Scholz, E., Schrijver, H. M., Schwab, M., Schwartz, R., Scott, J., Selmaj, K., Shafer, S., Sharrack, B., Shchukin, I. A., Shimizu, Y., Shotekov, P., Siever, A., Sigel, K. -O., Silliman, S., Simo, M., Simu, M., Sinay, V., Siquier, A. E., Siva, A., Skoda, O., Solomon, A., Stangel, M., Stefoski, D., Steingo, B., Stolyarov, I. D., Stourac, P., Strassburger-Krogias, K., Strauss, E., Stuve, O., Tarnev, I., Tavernarakis, A., Tello, C. R., Terzi, M., Ticha, V., Ticmeanu, M., Tiel-Wilck, K., Toomsoo, T., Tubridy, N., Tullman, M. J., Tumani, H., Turcani, P., Turner, B., Uccelli, A., Urtaza, F. J. O., Vachova, M., Valikovics, A., Walter, S., Van Wijmeersch, B., Vanopdenbosch, L., Weber, J. R., Weiss, S., Weissert, R., West, T., Wiendl, H., Wiertlewski, S., Wildemann, B., Willekens, B., Visser, L. H., Vorobeychik, G., Xu, X., Yamamura, T., Yang, Y. N., Yelamos, S. M., Yeung, M., Zacharias, A., Zelkowitz, M., Zettl, U., Zhang, M., Zhou, H., Zieman, U., Ziemssen, T., Bergmann A., Haas J., Mirabella M. (ORCID:0000-0002-7783-114X), and Terzi M.
- Abstract
Background: No treatment has consistently shown efficacy in slowing disability progression in patients with secondary progressive multiple sclerosis (SPMS). We assessed the effect of siponimod, a selective sphingosine 1-phosphate (S1P) receptor1,5 modulator, on disability progression in patients with SPMS. Methods: This event-driven and exposure-driven, double-blind, phase 3 trial was done at 292 hospital clinics and specialised multiple sclerosis centres in 31 countries. Using interactive response technology to assign numbers linked to treatment arms, patients (age 18–60 years) with SPMS and an Expanded Disability Status Scale score of 3·0–6·5 were randomly assigned (2:1) to once daily oral siponimod 2 mg or placebo for up to 3 years or until the occurrence of a prespecified number of confirmed disability progression (CDP) events. The primary endpoint was time to 3-month CDP. Efficacy was assessed for the full analysis set (ie, all randomly assigned and treated patients); safety was assessed for the safety set. This trial is registered with ClinicalTrials.gov, number NCT01665144. Findings: 1651 patients were randomly assigned between Feb 5, 2013, and June 2, 2015 (1105 to the siponimod group, and 546 to the placebo group). One patient did not sign the consent form, and five patients did not receive study drug, all of whom were in the siponimod group. 1645 patients were included in the analyses (1099 in the siponimod group and 546 in the placebo). At baseline, the mean time since first multiple sclerosis symptoms was 16·8 years (SD 8·3), and the mean time since conversion to SPMS was 3·8 years (SD 3·5); 1055 (64%) patients had not relapsed in the previous 2 years, and 918 (56%) of 1651 needed walking assistance. 903 (82%) patients receiving siponimod and 424 (78%) patients receiving placebo completed the study. 288 (26%) of 1096 patients receiving siponimod and 173 (32%) of 545 patients receiving placebo had 3-month CDP (hazard ratio 0·79, 95% CI 0·65–0·95; relative
- Published
- 2018
36. A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
- Author
-
Giovannoni, G, Comi, G, Cook, S, Rammohan, K, Rieckmann, P, Soelberg Sørensen, P, Vermersch, P, Sandberg Wollheim, M, Cuzick, J, Juliusson, G, Reingold, S, King, J, Pollard, J, Sedal, L, Aichner, F, Eggers, C, Dive, D, Medaer, R, Ferreira, M, Manchev, I, Milanov, I, Haralanov, L, Deleva, N, Petrova, N, Bozhinov, P, Zahariev, Z, Stamenov, B, Shotekov, P, Petrov, I, Moskov, R, Emond, F, Freedman, M, Grand'Maison, F, Jacques, F, Vorobeychik, G, Demarin, V, Kovacicek, M, Lusic, I, Perhat Bucevic, T, Havrdova, E, Talab, R, Kanovsky, P, Petersen, T, Gross Paju, K, Kalbe, I, Toomsoo, T, Elovaara, I, Eralinna, Jp, Reunanen, M, Clavelou, P, Damier, P, Debouverie, M, Edan, G, Gout, O, Labauge, P, Laplaud, D, Wiertlewski, S, Heidenreich, F, Mäurer, M, Kieseier, B, Limmroth, V, Oschmann, P, Schimrigk, S, Steinbrecher, A, Zettl, U, Ziemann, U, Karageorgiou, K, Kyritsis, A, Papadimitriou, A, Amato, Mp, Bernardi, G, Morra, Vb, Galgani, S, Gallo, Paolo, Patti, F, Marrosu, M, Pozzilli, C, Trojano, M, Mancardi, Gl, Gebeily, S, Koussa, S, Wehbe, M, Yamout, B, Vaitkus, A, Metra, M, Messouak, O, Mossaddaq, R, Slassi, I, Yahyaoui, M, Hupperts, Rm, Czlonkowska, A, Kozubski, W, Nyka, W, Selmaj, K, Szczudlik, A, Figueiredo, J, Pedrosa, R, Alifirova, V, Balyazin, V, Barbarash, O, Belova, A, Boyko, A, Gusev, E, Elchaninov, A, Jacoupov, E, Julev, N, Kotov, S, Kudryavtsev, A, Laskov, V, Lesnyak, O, Odinak, M, Pasechnik, E, Poverennonva, I, Skoromets, A, Spirin, N, Stolyarov, I, Vorobieva, O, Voskresenskaya, O, Zaslavskiy, L, Zonova, E, Bohlega, S, El Jumah, M, Drulovic, J, Nadj, C, Goebels, N, Schluep, M, Ayed Frih, M, Hentati, F, Mhiri, C, Mrabet, A, Mrissa, R, Idiman, E, Karabudak, R, Turan, Of, Ahmed, F, Constantinescu, C, Hawkins, C, Palace, J, Sharrack, B, Loganovsky, K, Moskovko, S, Nehrych, T, Voloshyna, Np, Carlini, W, English, J, Garmany, G, Glyman, S, Huddlestone, J, Hurwitz, B, Kresa Reahl, K, Mikol, D, Pardo, G, Rao, H, Reif, M, Thrower, B, Royal, W, Webb, R, Wynn, D, Naga, C, Allen, N, Lin, K, Stefoski, D, Balabanov, R., Klinische Neurowetenschappen, RS: MHeNs School for Mental Health and Neuroscience, G., Giovannoni, G., Comi, S., Cook, K., Rammohan, P., Rieckmann, P. S., Sorensen, P., Vermersch, P., Chang, A., Hamlett, B., Musch, S. J., Greenberg, Altri, and BRESCIA MORRA, Vincenzo
- Subjects
Male ,Medizin ,Placebo-controlled study ,Administration, Oral ,Relapsing-Remitting ,drug therapy/pathology ,Gastroenterology ,Disability Evaluation ,Cladribine ,Hazard ratio ,Brain ,General Medicine ,Middle Aged ,Administration ,Oral, Adolescent, Adult, Aged, Analysis of Variance, Brain ,pathology, Cladribine ,adverse effects/therapeutic use, Disability Evaluation, Disease Progression, Double-Blind Method, Female, Herpes Zoster ,etiology, Humans, Immunosuppressive Agents ,adverse effects/therapeutic use, Intention to Treat Analysis, Lymphopenia ,chemically induced, Magnetic Resonance Imaging, Male, Middle Aged, Multiple Sclerosis ,drug therapy/pathology, Young Adult ,Magnetic Resonance Imaging ,Intention to Treat Analysis ,adverse effects/therapeutic use ,Disease Progression ,chemically induced ,Female ,Immunosuppressive Agents ,medicine.drug ,Oral ,Adult ,medicine.medical_specialty ,Multiple Sclerosis ,Adolescent ,etiology ,cladribine ,immunomodulation ,multiple sclerosis ,trial ,Lower risk ,Placebo ,DIAGNOSIS ,Herpes Zoster ,Young Adult ,Multiple Sclerosis, Relapsing-Remitting ,Double-Blind Method ,Lymphopenia ,Internal medicine ,medicine ,Humans ,Adverse effect ,Aged ,Analysis of Variance ,business.industry ,MS ,medicine.disease ,Confidence interval ,Surgery ,CELLS ,pathology ,Lymphocytopenia ,business - Abstract
Cladribine provides immunomodulation through selective targeting of lymphocyte subtypes. We report the results of a 96-week phase 3 trial of a short-course oral tablet therapy in patients with relapsing–remitting multiple sclerosis. We randomly assigned 1326 patients in an approximate 1:1:1 ratio to receive one of two cumulative doses of cladribine tablets (either 3.5 mg or 5.25 mg per kilogram of body weight) or matching placebo, given in two or four short courses for the first 48 weeks, then in two short courses starting at week 48 and week 52 (for a total of 8 to 20 days per year). The primary end point was the rate of relapse at 96 weeks. Among patients who received cladribine tablets (either 3.5 mg or 5.25 mg per kilogram), there was a significantly lower annualized rate of relapse than in the placebo group (0.14 and 0.15, respectively, vs. 0.33 ; P
- Published
- 2010
- Full Text
- View/download PDF
37. Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study
- Author
-
Barbin, L. (Laetitia), Rousseau, C. (Chloe), Jousset, N. (Natacha), Casey, R. (Romain), Debouverie, M. (Marc), Vukusic, S. (Sandra), De Seze, J. (Jerome), Brassat, D. (David), Wiertlewski, S. (Sandrine), Brochet, B. (Bruno), Pelletier, J. (Jean), Vermersch, P. (Patrick), Edan, G. (Gilles), Lebrun-Frenay, C. (Christine), Clavelou, P. (Pierre), Thouvenot, E. (Eric), Camdessanché, J. (Jean-Philippe), Tourbah, A. (Ayman), Stankoff, B. (Bruno), Al Khedr, A. (Abdullatif), Cabre, P. (Philippe), Papeix, C. (Caroline), Berger, E. (Eric), Heinzlef, O. (Olivier), Debroucker, T. (Thomas), Moreau, T. (Thibault), Gout, O. (Olivier), Bourre, B. (Bertrand), Créange, A. (Alain), Labauge, P. (Pierre), Magy, L. (Laurent), Defer, G. (Gilles), Foucher, Y. (Yohann), Laplaud, D. (David A), CFSEP and OFSEP groups, Jonchère, Laurent, Centre d’Investigation Clinique de Nantes (CIC Nantes), Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre hospitalier universitaire de Nantes (CHU Nantes), Biostatistique, Pharmacoépidémiologie et Mesures Subjectives en Santé, PRES Université Nantes Angers Le Mans (UNAM), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM), ReLSEP, Lorraine Register of MS, EA 4360, Department of Neurology, CHU Nancy, Department of Neurology, CHU Lyon, Service de Neurologie [Lyon], Centre de Physiopathologie Toulouse Purpan (CPTP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service de Neurologie, Centre hospitalier universitaire de Nantes (CHU Nantes)-Hôpital Guillaume-et-René-Laennec [Saint-Herblain], Service de neurologie [Bordeaux], CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Université de Bordeaux (UB), Pôle de Neurosciences Cliniques, Department of Neurology, Hôpital de la Timone [CHU - APHM] (TIMONE), Inflammation: mécanismes et régulation et interactions avec la nutrition et les candidoses, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille, Droit et Santé, Laboratoire d'Immunologie (EA 2686), Université de Lille, Droit et Santé, Service de neurologie D, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Vision, Action et Gestion d'informations en Santé (VisAGeS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Inria Rennes – Bretagne Atlantique, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-SIGNAUX ET IMAGES NUMÉRIQUES, ROBOTIQUE (IRISA-D5), Institut de Recherche en Informatique et Systèmes Aléatoires (IRISA), Université de Rennes (UR)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université de Bretagne Sud (UBS)-École normale supérieure - Rennes (ENS Rennes)-Institut National de Recherche en Informatique et en Automatique (Inria)-Télécom Bretagne-CentraleSupélec-Centre National de la Recherche Scientifique (CNRS)-Université de Rennes (UR)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université de Bretagne Sud (UBS)-École normale supérieure - Rennes (ENS Rennes)-Institut National de Recherche en Informatique et en Automatique (Inria)-Télécom Bretagne-CentraleSupélec-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche en Informatique et Systèmes Aléatoires (IRISA), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université de Bretagne Sud (UBS)-École normale supérieure - Rennes (ENS Rennes)-Télécom Bretagne-CentraleSupélec-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Nice (CHU Nice), CHU Clermont-Ferrand, CHU Saint-Etienne, Hôpital Maison Blanche, Centre Hospitalier Universitaire de Reims (CHU Reims), Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Service Hospitalier Frédéric Joliot (SHFJ), Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de Neurologie [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU de la Martinique [Fort de France], CHU Pitié-Salpêtrière [AP-HP], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Service de Neurologie [CHRU Besançon], Service de Neurologie [CHU de Poissy], CHU De Poissy, Service de Neurologie générale, vasculaire et dégénérative (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Fondation Ophtalmologique Rothschild, Excitabilité nerveuse et thérapeutique (ENT), Hôpital Henri Mondor-EA 4391, Service de Physiologie Explorations Fonctionnelles-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre de résonance magnétique biologique et médicale (CRMBM), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Centre National de la Recherche Scientifique (CNRS), CHU Limoges, Service de Neurologie [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Biostatistique, Recherche Clinique et Mesures Subjectives en Santé, Université de Nantes (UN), Centre de Recherche en Transplantation et Immunologie (U1064 Inserm - CRTI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Fondation Ophtalmologique Adolphe de Rothschild [Paris], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-Université de Bretagne Sud (UBS)-École normale supérieure - Rennes (ENS Rennes)-Institut National de Recherche en Informatique et en Automatique (Inria)-Télécom Bretagne-CentraleSupélec-Centre National de la Recherche Scientifique (CNRS)-Université de Rennes 1 (UR1), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-Université de Bretagne Sud (UBS)-École normale supérieure - Rennes (ENS Rennes)-Institut National de Recherche en Informatique et en Automatique (Inria)-Télécom Bretagne-CentraleSupélec-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche en Informatique et Systèmes Aléatoires (IRISA), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-Université de Bretagne Sud (UBS)-École normale supérieure - Rennes (ENS Rennes)-Télécom Bretagne-CentraleSupélec-Centre National de la Recherche Scientifique (CNRS), CentraleSupélec-Télécom Bretagne-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de Recherche en Informatique et en Automatique (Inria)-École normale supérieure - Rennes (ENS Rennes)-Université de Bretagne Sud (UBS)-Centre National de la Recherche Scientifique (CNRS)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-CentraleSupélec-Télécom Bretagne-Université de Rennes 1 (UR1), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-Institut de Recherche en Informatique et Systèmes Aléatoires (IRISA), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École normale supérieure - Rennes (ENS Rennes)-Université de Bretagne Sud (UBS)-Centre National de la Recherche Scientifique (CNRS)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-CHU Pitié-Salpêtrière [AP-HP], Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-EA 4391, Service de Physiologie Explorations Fonctionnelles-Hôpital Henri Mondor, Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hospices Civils de Lyon (HCL), Centre de Physiopathologie Toulouse Purpan ex IFR 30 et IFR 150 (CPTP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-CHU Pitié-Salpêtrière [APHP], CHU Saint-Antoine [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Saint-Antoine [APHP], CHU Pitié-Salpêtrière [APHP], Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon), and Service de Neurologie [CHU Besançon]
- Subjects
Male ,[SDV]Life Sciences [q-bio] ,Aucun ,diagnosis ,drug therapy ,epidemiology ,Cohort Studies ,0302 clinical medicine ,Natalizumab ,Medicine ,030212 general & internal medicine ,10. No inequality ,Fingolimod ,3. Good health ,[SDV] Life Sciences [q-bio] ,Treatment Outcome ,Cohort ,Female ,France ,Immunosuppressive Agents ,medicine.drug ,Cohort study ,Adult ,medicine.medical_specialty ,Multiple Sclerosis ,Sciences du Vivant [q-bio]/Neurosciences [q-bio.NC] ,Article ,03 medical and health sciences ,Multiple Sclerosis, Relapsing-Remitting ,Fingolimod Hydrochloride ,Internal medicine ,Humans ,Immunologic Factors ,Expanded Disability Status Scale ,business.industry ,Multiple sclerosis ,medicine.disease ,Surgery ,Propylene Glycols ,therapeutic use ,Propensity score matching ,Neurology (clinical) ,business ,030217 neurology & neurosurgery ,Follow-Up Studies - Abstract
OBJECTIVE: To compare natalizumab and fingolimod on both clinical and MRI outcomes in patients with relapsing-remitting multiple sclerosis (RRMS) from 27 multiple sclerosis centers participating in the French follow-up cohort Observatoire of Multiple Sclerosis. METHODS: Patients with RRMS included in the study were aged from 18 to 65 years with an Expanded Disability Status Scale score of 0-5.5 and an available brain MRI performed within the year before treatment initiation. The data were collected for 326 patients treated with natalizumab and 303 with fingolimod. The statistical analysis was performed using 2 different methods: logistic regression and propensity scores (inverse probability treatment weighting). RESULTS: The confounder-adjusted proportion of patients with at least one relapse within the first and second year of treatment was lower in natalizumab-treated patients compared to the fingolimod group (21.1% vs 30.4% at first year, p = 0.0092; and 30.9% vs 41.7% at second year, p = 0.0059) and supported the trend observed in nonadjusted analysis (21.2% vs 27.1% at 1 year, p = 0.0775). Such statistically significant associations were also observed for gadolinium (Gd)-enhancing lesions and new T2 lesions at both 1 year (Gd-enhancing lesions: 9.3% vs 29.8%, p < 0.0001; new T2 lesions: 10.6% vs 29.6%, p < 0.0001) and 2 years (Gd-enhancing lesions: 9.1% vs 22.1%, p = 0.0025; new T2 lesions: 16.9% vs 34.1%, p = 0.0010) post treatment initiation. CONCLUSION: Taken together, these results suggest the superiority of natalizumab over fingolimod to prevent relapses and new T2 and Gd-enhancing lesions at 1 and 2 years. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that for patients with RRMS, natalizumab decreases the proportion of patients with at least one relapse within the first year of treatment compared to fingolimod. comparative study journal article multicenter study observational study research support, non-u.s. gov't 2016 Feb 23 2016 01 29 imported
- Published
- 2016
- Full Text
- View/download PDF
38. Premier cas clinique de bactériémie à Gordonia aichiensis
- Author
-
Thomas, E., primary, Lejeune, F., additional, Caillon, J., additional, Wiertlewski, S., additional, and Crémet, L., additional
- Published
- 2017
- Full Text
- View/download PDF
39. Comparative efficacyof fingolimod versus natalizumab in multiple sclerosis: a prospective multicenter observational study
- Author
-
Laplaud, D. A., Barbin, L., Rousseau, C., Jousset, N., Romain Casey, Marc Debouverie, Vukusic, S., Seze, J., Brassat, D., Wiertlewski, S., Bruno Brochet, Jean Pelletier, Patrick Vermersch, Gilles Edan, Christine Lebrun-Frenay, Pierre Clavelou, Eric Thouvenot, P Camdessanche, J., Ayman Tourbah, Bruno Stankoff, Al Khedr, A., Philippe Cabre, Papeix, C., Eric Berger, Olivier Heinzlef, Debroucker, T., Thibault Moreau, Gout, O., Bertrand Bourre, Creange, A., Pierre Labauge, Magy, L., Gilles Defer, Foucher, Y., Centre de Recherche en Transplantation et Immunologie (U1064 Inserm - CRTI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Centre d’Investigation Clinique de Nantes (CIC Nantes), Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre hospitalier universitaire de Nantes (CHU Nantes), Biostatistique, Recherche Clinique et Mesures Subjectives en Santé, Université de Nantes (UN), Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hospices Civils de Lyon (HCL), Centre de résonance magnétique biologique et médicale (CRMBM), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Centre National de la Recherche Scientifique (CNRS), Neurologie, maladies neuro-musculaires [Hôpital de la Timone - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Service de Neurologie [Rennes], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Maison Blanche, Centre Hospitalier Universitaire de Reims (CHU Reims), Département de Neurologie [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-IFR70-CHU Pitié-Salpêtrière [APHP], Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre hospitalier universitaire de Nantes (CHU Nantes), Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Service de Neurologie [Rennes] = Neurology [Rennes], CHU Pontchaillou [Rennes], Service de Neurologie [CHU Pitié-Salpêtrière], IFR70-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Jonchère, Laurent, Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Institut National de la Recherche Agronomique (INRA)
- Subjects
[SDV] Life Sciences [q-bio] ,[SDV]Life Sciences [q-bio] ,ComputingMilieux_MISCELLANEOUS - Abstract
International audience; no abstract
- Published
- 2015
40. A French observational study about treatment failure under fingolimod in 91 multiple sclerosis patients
- Author
-
Carra Dallière, Clarisse, Fisselier, M., Cohen, M., Ayrignac, X., Le Page, E., Edan, Gilles, Burghgraeve, V., Papeix, C., Lubetzki, Catherine, Maillart, E., Seze, J., Collongues, N., Gout, O., Deschamps, R., Laplaud, David, Wiertlewski, S., Pelletier, Jean, Audoin, Bertrand, Brassat, D., Clanet, M., Peaureaux, D., Guennoc, A. -M., Ruet, A., Brochet, Bruno, Ouallet, J. -C., Debouverie, Marc, Pittion, S., Fromont, A., Moreau, Thibault, Taithe, F., Clavelou, Pierre, Zephyr, H., Outteryck, Olivier, Vermersch, Patrick, Charif, M., Thouvenot, Eric, Mazzola, L., Camdessanche, J. -P., Bourre, Bertrand, Lalu, T., Magy, L., Grimaud, J., Lebrun, C., Labauge, Pierre, Jonchère, Laurent, CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Service de Neurologie [Rennes] = Neurology [Rennes], CHU Pontchaillou [Rennes], Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Neurologie [CHU Pitié-Salpêtrière], IFR70-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Strasbourg, Centre de résonance magnétique biologique et médicale (CRMBM), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Centre National de la Recherche Scientifique (CNRS), Neurologie, maladies neuro-musculaires [Hôpital de la Timone - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
[SDV] Life Sciences [q-bio] ,[SDV]Life Sciences [q-bio] ,ComputingMilieux_MISCELLANEOUS - Abstract
International audience; no abstract
- Published
- 2015
41. Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients.
- Author
-
On behalf of the Société Francophone de la Sclérose en Plaques, Michel, L., Lefrere, F., Laplaud, D. A., Derkinderen, P., Wiertlewski, S., Balloy, G., Lejeune, P., Devos, P., N'Kendjuo, J.-B., Coustans, M., Auffray-Calvier, E., Daumas-Duport, B., Brosset, C., de Seze, J., Pelletier, J., Suchet, L., Lebrun, C., Cohen, M., and Vermersch, P.
- Subjects
TISSUE wounds ,CENTRAL nervous system ,MULTIPLE sclerosis ,PATIENTS ,HEMIPARESIS - Abstract
Background: Tumefactive demyelinating lesions of the central nervous system can be the initial presentation in various pathological entities [multiple sclerosis (the most common), Balo’s concentric sclerosis, Schilder’s disease and acute disseminated encephalomyelitis] with overlapping clinical presentation. The aim of our study was to better characterize these patients.Methods: Eighty-seven patients (62 women and 25 men) from different MS centers in France were studied retrospectively. Inclusion criteria were (1) a first clinical event (2) MRI showing one or more large demyelinating lesions (20 mm or more in diameter) with mass-like features. Patients with a previous demyelinating event (i.e. confirmed multiple sclerosis) were excluded.Results: Mean age at onset was 26 years. The most common initial symptoms (67% of the patients) were hemiparesis or hemiplegia. Aphasia, headache and cognitive disturbances (i.e. atypical symptoms for demyelinating diseases) were observed in 15, 18 and 15% of patients, respectively. The mean largest diameter of the tumefactive lesions was 26.9 mm, with gadolinium enhancement in 66 patients (81%). Twenty-one patients (24%) had a single tumefactive lesion. During follow-up (median time 5.7 years) 4 patients died, 70 patients improved or remained stable and 12 worsened. 86% of patients received initial corticosteroid treatment, and 73% received disease-modifying therapy subsequently. EDSS at the end of the follow-up was 2.4 ± 2.6 (mean ± SD).Conclusion: This study provides further evidence that the clinical course of MS presenting with large focal tumor-like lesions does not differ from that of classical relapsing-remitting MS, once the noisy first relapsing occurred. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
42. THE PREVENTION OF POST-PARTUM RELAPSES WITH PROGESTIN AND ESTRADIOL IN MULTIPLE SCLEROSIS (POPART'MUS) TRIAL: RATIONALE, OBJECTIVES AND STATE OF ADVANCEMENT
- Author
-
Vukusic, S, Ionescu, I, El Etr, M, Schumacher, M, Baulieu, Ee, Cornu, C, Confavreux, C, Clanet, M, Brassat, D, Viala, F, Moreau, T, Couvreur, G, Madinier, G, Debouverie, M, Laplaud, D, Wiertlewski, S, Clavelou, P, Aufauvre, D, Pelletier, J, Rico Lamy, A, Edan, G, Le Page, E, Rumbach, L, Berger, E, Hautecoeur, P, Lebrun Frenay, C, Labauge, P, Castelnovo, G, Heinzlef, O, Brochet, B, Ouallet, Jc, Clerc, C, Rieu, L, Lauxerois, M, Hinzelin, G, Froment Sallansonnet, M, Stankoff, B, Borgel, F, Toureille Borlet, L, Minier, D, Coustans, M, Tourniaire, P, Durelli, Luca, Tavella, A, Trojano, M, Carrozzo, A, Patti, F, Zaffaroni, M, and Motti, L.
- Published
- 2009
43. GEMSEP1 : a new drug candidate for secondary progressive form of Multiple Sclerosis
- Author
-
Geffard, M., Tranchant, C., Fleury, M., Wiertlewski, S., Guennoc, A.M., Dabadie, M.P., Laboratoire de physique des interactions ondes matières (LPIOM), Université Sciences et Technologies - Bordeaux 1-École Nationale Supérieure de Chimie et de Physique de Bordeaux (ENSCPB)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de l'intégration, du matériau au système (IMS), Université Sciences et Technologies - Bordeaux 1-Institut Polytechnique de Bordeaux-Centre National de la Recherche Scientifique (CNRS), Service de Neurologie [Strasbourg], CHU Strasbourg-Hopital Civil, Immunochemistry Department Gemacbio S.A., and Gemacbio S.A
- Subjects
[SDV.BBM.BP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Biophysics ,[SDV.TOX]Life Sciences [q-bio]/Toxicology - Published
- 2005
44. Étude rétrospective multicentrique évaluant le retentissement des traitements utilisés pour la fécondation in vitro sur le risque de poussées de Sclérose en plaques
- Author
-
Michel, L., Foucher, Y., De Sèze, J., Vukusic, S., Confavreux, C., Brassat, D., Clavelou, P., Ouallet, J.-C., Brochet, B., Pelletier, J., Labauge, P., Lebrun, C., Lefrere, F., Jacq-Foucher, M., Wiertlewski, S., and Laplaud, D.-A.
- Published
- 2010
- Full Text
- View/download PDF
45. Mycophenolate mofetil in multiple sclerosis: a multicentre retrospective study on 344 patients
- Author
-
Michel, L., primary, Vukusic, S., additional, De Seze, J., additional, Ducray, F., additional, Ongagna, J. C., additional, Lefrere, F., additional, Jacq-Foucher, M., additional, Confavreux, C., additional, Wiertlewski, S., additional, and Laplaud, D. A., additional
- Published
- 2013
- Full Text
- View/download PDF
46. Mycophenolate Mofetil as a Monotherapy in Multiple Sclerosis: A Multicenter Retrospective Study on 362 Patients (P04.144)
- Author
-
Michel, L., primary, Vukusic, S., additional, De Seze, J., additional, Ducray, F., additional, Ongagna, J.-C., additional, Confavreux, C., additional, Laplaud, D., additional, and Wiertlewski, S., additional
- Published
- 2012
- Full Text
- View/download PDF
47. Étude prospective, observationnelle de la sécurité d’emploi de la 3,4-diaminopyridine base
- Author
-
Chincholle, A., primary, Rousselet, E., additional, Trainaud, A., additional, Chiffoleau, A., additional, Pennetier, M., additional, Laplaud, D., additional, Wiertlewski, S., additional, and Flet, L., additional
- Published
- 2012
- Full Text
- View/download PDF
48. Clinics and urodynamics in the cerebellar presentation of multiple sclerosis: A risky situation?
- Author
-
Le Fort, M., primary, Wiertlewski, S., additional, Laplaud, D., additional, Michel, L., additional, Reiss, B., additional, Labat, J.-J., additional, Le Normand, L., additional, and Perrouin-Verbe, B., additional
- Published
- 2011
- Full Text
- View/download PDF
49. Hyperréflexie autonome et neuromyélite optique de Devic : une association logique mais méconnue ; à partir d’un cas
- Author
-
Le Fort, M., primary, Laplaud, D., additional, Wiertlewski, S., additional, and Perrouin-Verbe, B., additional
- Published
- 2011
- Full Text
- View/download PDF
50. Autonomous hyperreflexia and Devic’ optic neuromyelitis: A logical but poorly recognized combination: a case report
- Author
-
Le Fort, M., primary, Laplaud, D., additional, Wiertlewski, S., additional, and Perrouin-Verbe, B., additional
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.